Jan 032023
Drug Name |
Active Ingredient(s) |
Approval Date |
FDA-Approved Use on Approval Date |
Press Release |
Drug Trials Snapshot |
NexoBrid | anacaulase-bcdb | 12/28/2022 | To remove eschar in adults with deep partial thickness or full thickness thermal burns | Drug Trials Snapshot | |
Briumvi | ublituximab-xiiy | 12/28/2022 | To treat relapsing forms of multiple sclerosis | Drug Trials Snapshot | |
Xenoview | hyperpolarized Xe-129 | 12/23/2022 | To evaluate pulmonary function and imaging | Drug Trials Snapshot | |
Lunsumio | mosunetuzumab-axgb | 12/22/2022 | To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphoma | Drug Trials Snapshot | |
Sunlenca | lenacapavir | 12/22/2022 | To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations | Press Release | Drug Trials Snapshot |
Krazati | adagrasib | 12/12/2022 | To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy | Drug Trials Snapshot | |
Rezlidhia | olutasidenib | 12/1/2022 | To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation | Drug Trials Snapshot |
Sorry, the comment form is closed at this time.